CG Oncology (NASDAQ:CGON) Director Leonard Post Sells 5,000 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard Post sold 5,000 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $65.00, for a total value of $325,000.00. Following the completion of the sale, the director owned 5,000 shares in the company, valued at approximately $325,000. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

CG Oncology Trading Down 0.8%

Shares of CGON stock traded down $0.52 on Tuesday, reaching $65.73. 846,571 shares of the company’s stock were exchanged, compared to its average volume of 1,179,023. The company’s fifty day simple moving average is $64.22 and its 200 day simple moving average is $57.37. CG Oncology, Inc. has a 52 week low of $23.65 and a 52 week high of $75.50. The stock has a market capitalization of $5.80 billion, a PE ratio of -28.21 and a beta of 0.31.

CG Oncology (NASDAQ:CGON) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The business had revenue of $1.08 million during the quarter, compared to the consensus estimate of $0.45 million. As a group, sell-side analysts predict that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Whittier Trust Co. of Nevada Inc. purchased a new stake in CG Oncology during the fourth quarter valued at approximately $27,000. NFSG Corp acquired a new stake in shares of CG Oncology in the 1st quarter worth $34,000. Comerica Bank grew its stake in CG Oncology by 100.4% during the 4th quarter. Comerica Bank now owns 1,028 shares of the company’s stock worth $43,000 after buying an additional 515 shares during the last quarter. Fifth Third Bancorp acquired a new position in CG Oncology during the 1st quarter valued at about $74,000. Finally, KBC Group NV purchased a new stake in CG Oncology in the first quarter valued at about $78,000. Institutional investors own 26.56% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on CGON. Wolfe Research initiated coverage on shares of CG Oncology in a research note on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Truist Financial reaffirmed a “buy” rating and set a $82.00 price target (up from $77.00) on shares of CG Oncology in a research note on Thursday, May 14th. Wedbush boosted their price target on CG Oncology from $77.00 to $80.00 and gave the company an “outperform” rating in a report on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of CG Oncology in a research note on Monday, April 20th. Finally, Wall Street Zen downgraded CG Oncology from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, CG Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $81.73.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.